Abstract
Innovative medicines are defined as the medicines that contain an active substance or combination of active substances that have not been authorised before. Conducting health technology assessment (HTA) in silico may inform manufacturers of portfolio prioritisation and evidence generation strategy. This study aims to identify whether artificial intelligence algorithms may predict reimbursement decision for innovative drugs in Scotland.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
